

Evaluation Report for Category B, Subcategory 3.11 Application

Application Number: 2021-5814 **Application:** New Pest

Product: Lumiderm Insecticide Seed Treatment

Registration Number: 30894

Active ingredients (a.i.): Cyantraniliprole

PMRA Document Number: 3325174

Background

Lumiderm Insecticide Seed Treatment, containing cyantraniliprole at 625 g/L, is a suspension insecticide registered to reduce early season feeding damage of certain insects on canola, rapeseed, oilseed mustard and soybeans. For specific details of uses, application rates and methods, precautions, restrictions, and personal protective equipment requirements, refer to the product label.

Purpose of Application

The purpose of this application is to add a claim of reducing early season feeding damage caused by cutworms on soybeans to the label of Lumiderm Insecticide Seed Treatment.

Chemistry, Health and Environmental Assessments

A chemistry assessment was not required because there was no change to product chemistry. Health and environmental assessments were not required because the rate for management of early season feeding damage caused by cutworms on soybeans is within the registered rate range for management of other pests on soybeans following the same application timing.

Value Assessment

Data from two efficacy studies, as well as claims for the same pests on other crops on the registered label of Lumiderm Insecticide Seed Treatment provided evidence that applications to soybean seeds at 0.0375 - 0.075 mg a.i./seed can reduce early season feeding damage caused by cutworms. The addition of this claim to the label of Lumiderm Insecticide Seed Treatment will provide soybean growers with an alternative product for use to manage early season feeding damage caused by cutworms.



Conclusion

The PMRA has completed an assessment of the subject application and has concluded that the submitted information is adequate to support the following claim:

• Reduction of early season feeding damage caused by cutworms on soybeans at 0.0375-0.075 mg a.i./seed.

References

3282889	2021, Summary_USA-21-SOY-INS81_Final, DACO: 10.1,10.2
3282890	2021, Trial Report_USA-21-SOY-INS81_1, DACO: 10.2.3.3
3282891	2021, Trial Report_USA-21-SOY-INS81_2, DACO: 10.2.3.3

© Her Majesty the Queen in Right of Canada, as represented by the Minister of Health Canada, 2022

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.